Enadenotucirev is under clinical development by PsiOxus Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Enadenotucirev’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Enadenotucirev Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Enadenotucirev (ColoAd1) is under development for the treatment of solid tumors including metastatic bladder cancer, salivary gland cancer, fallopian tube cancer, squamous and non-squamous non-small cell lung cancer, primary peritoneal cancer, colon cancer, urothelial cell carcinoma, head and neck cancer squamous cell carcinoma, advanced epithelial tumor. It is administered through intratumoral, intravenous and intraperitoneal routes. It is a chimeric oncolytic vaccine consists of chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions. It was also under development for metastatic colorectal cancer, breast cancer, platinum resistant ovarian cancer, renal cell carcinoma.
PsiOxus Therapeutics overview
PsiOxus Therapeutics (PsiOxus), formerly Myotec Therapeutics, is a drug company that develops novel therapeutics for cancer and other clinically unmet diseases. It provides pipeline product portfolio such as an oncolytic vaccine and a dual action anabolic catabolic transforming agent. The company also has an antibody armed oncolytic platform under development. PsiOxus’s products find application in the treatment of various cancer diseases such as cachexia, sarcopenia, metastatic cancer and solid tumours, among others. It holds expertise in enhancing the therapeutic potency, safety and delivery kinetics through genetic modification to produce cancer vaccines. PsiOxus is headquartered in Abingdon, Oxfordshire, the UK.
Quick View Enadenotucirev LOA Data
|Highest Development Stage|